유전자 치료 시장 규모 및 예측, 세계 및 지역의 점유율, 동향, 성장 기회 분석 리포트 : 벡터별, 적응증별, 딜리버리 모드별, 지역별

The gene therapy market size is expected to grow from US$ 5.11 billion in 2023 to US$ 25.69 billion by 2031; it is projected to register a CAGR of 14.3% during 2023-2031.

Gene therapy is a pioneering treatment method that uses genes to treat diseases. Gene therapy offers a promising approach to treat and cure diseases by introducing genetic material into a patient's cells to replace or correct abnormal genes. Gene therapy can be classified into in-vivo and ex-vivo gene therapy. This innovative treatment method has gained significant attention and investment in recent years, leading to advancements in gene therapy techniques and technologies. The gene therapy market growth is attributed to the increasing burden of genetic diseases and the rising number of FDA approvals of gene therapies. However, the high cost of gene therapy products hinders the growth of the gene therapy market.

Researchers are working on making gene therapy available in clinics. A wide range of product portfolios are in the pipeline at various universities and institutes, and revenue generation is expected to increase during the forecast period. Following the FDA's approval of the first gene therapy, the number of clinical trials for gene therapy surged dramatically from 2017 to 2018. About 1,986 products, including CAR T-cell treatments and other genetically engineered cell therapies, are currently under development, according to the American Society of Gene & Cell Therapy. Over the projection period, the robust pipeline is anticipated to offer new opportunities for the growth of the gene therapy market.

Vectors-Based Insights

Based on vectors, the gene therapy market is categorized into non-viral vectors and viral vectors. The viral vectors segment held a significant gene therapy market share in 2023. It is anticipated to record a higher CAGR in the market during the forecast period. Viral vectors have the ability to competently deliver genetic material into target cells. They are derived from viruses that naturally can infect cells and transfer their genetic material. This makes them highly effective in delivering therapeutic genes into the cells of patients. In addition, viral vectors offer a high level of specificity and selectivity. They can be engineered to target particular types of cells or tissues, allowing for targeted delivery of therapeutic genes. This is particularly important in gene therapy, as it reduces the risk of off-target effects and enhances the effectiveness of the treatment. Moreover, viral vectors have been extensively studied and optimized over the years, leading to the development of safer and more efficient vector systems. Advances in vector design and manufacturing technologies have improved the safety profile and scalability of viral vectors, making them more suitable for clinical applications.

According to the analysis from clinicaltrials.gov, ~58% of gene therapies under development are using viral vectors. The most commonly employed viral vector for gene therapy is adeno-associated virus, owing to its ability to deliver genes to non-dividing cells where the gene has a long-term therapeutic impact. Different varieties of adeno-associated viruses target different cells, making them a suitable transporter of genetic material to desired locations inside the body, providing a customized treatment. In addition, viral vectors display low immunogenicity, safety, and long-term transient expression. Overall, the growing demand for safe and effective gene therapies, along with the advantages offered by viral vectors, has contributed to the segment's significant growth, positively influencing the gene therapy market growth.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the gene therapy market report.

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 Market Definition, Assumptions and Limitations
• 1.3 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gene Therapy Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Gene Therapy Market - Key Market Dynamics

• 5.1 Key Market Drivers
• 5.2 Key Market Restraints
• 5.3 Key Market Opportunities
• 5.4 Future Trends
• 5.5 Impact Analysis of Drivers and Restraints

6. Gene Therapy Market - Global Market Analysis

• 6.1 Gene Therapy - Global Market Overview
• 6.2 Gene Therapy - Global Market and Forecast to 2031

7. Gene Therapy Market - Revenue Analysis (USD Million) - By Vector Type, 2021-2031

• 7.1 Overview
• 7.2 Viral Vector
• 7.3 Non-Viral Vector

8. Gene Therapy Market - Revenue Analysis (USD Million) - By Method, 2021-2031

• 8.1 Overview
• 8.2 Ex-Vivo
• 8.3 In-Vivo

9. Gene Therapy Market - Revenue Analysis (USD Million) - By Application, 2021-2031

• 9.1 Overview
• 9.2 Neurological Disorders
• 9.3 Cancer
• 9.4 Duchenne Muscular Dystrophy
• 9.5 Hepatological Diseases
• 9.6 Other Indications

10. Gene Therapy Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

• 10.1 North America
  • 10.1.1 North America Gene Therapy Market Overview
  • 10.1.2 North America Gene Therapy Market Revenue and Forecasts to 2031
  • 10.1.3 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Vector Type
  • 10.1.4 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Method
  • 10.1.5 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Application
  • 10.1.6 North America Gene Therapy Market Revenue and Forecasts and Analysis - By Countries
    • 10.1.6.1 United States Gene Therapy Market
      • 10.1.6.1.1 United States Gene Therapy Market, by Vector Type
      • 10.1.6.1.2 United States Gene Therapy Market, by Method
      • 10.1.6.1.3 United States Gene Therapy Market, by Application
    • 10.1.6.2 Canada Gene Therapy Market
      • 10.1.6.2.1 Canada Gene Therapy Market, by Vector Type
      • 10.1.6.2.2 Canada Gene Therapy Market, by Method
      • 10.1.6.2.3 Canada Gene Therapy Market, by Application
    • 10.1.6.3 Mexico Gene Therapy Market
      • 10.1.6.3.1 Mexico Gene Therapy Market, by Vector Type
      • 10.1.6.3.2 Mexico Gene Therapy Market, by Method
      • 10.1.6.3.3 Mexico Gene Therapy Market, by Application

Note - Similar analysis would be provided for below mentioned regions/countries

• 10.2 Europe
  • 10.2.1 Germany
  • 10.2.2 France
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific
  • 10.3.1 Australia
  • 10.3.2 China
  • 10.3.3 India
  • 10.3.4 Japan
  • 10.3.5 South Korea
  • 10.3.6 Rest of Asia-Pacific
• 10.4 Middle East and Africa
  • 10.4.1 South Africa
  • 10.4.2 Saudi Arabia
  • 10.4.3 U.A.E
  • 10.4.4 Rest of Middle East and Africa
• 10.5 South and Central America
  • 10.5.1 Brazil
  • 10.5.2 Argentina
  • 10.5.3 Rest of South and Central America

11. Industry Landscape

• 11.1 Mergers and Acquisitions
• 11.2 Agreements, Collaborations, Joint Ventures
• 11.3 New Product Launches
• 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

• 12.1 Heat Map Analysis by Key Players
• 12.2 Company Positioning and Concentration

13. Gene Therapy Market - Key Company Profiles

• 13.1 Novartis AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

• 13.2 Astellas Pharma Inc
• 13.3 Bristol-Myers Squibb Company
• 13.4 Bluebird Bio Inc.
• 13.5 Sanofi
• 13.6 F. Hoffmann-La Roche Ltd.
• 13.7 Daiichi Sankyo
• 13.8 CSL Behring
• 13.9 Biogen
• 13.10 Oxford Biomedica

14. Appendix

• 14.1 Glossary
• 14.2 About The Insight Partners
• 14.3 Market Intelligence Cloud